Diligence memo · auto-generated · as of July 2, 2026
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
60 Degrees Pharmaceuticals, Inc. operates in Pharmaceuticals, based in WASHINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
60 Degrees Pharmaceuticals, Inc. has raised $3.9M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.8M on 2022-05-19.
Most recent recorded round closed around 2025-02-05.
Valuation (modeled)modeled
Provath models 60 Degrees Pharmaceuticals, Inc. at approximately $3.7M (range $813K–$8.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 17 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 38% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: Kairos Pharma, LTD., Branch Therapeutics, Inc., ResBiotic Nutrition, Inc., Califia Pharma, Inc., BTB Therapeutics, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.